• Journal of Ginseng Research
• /
• v.18 no.3
• /
• pp.151-159
• /
• 1994

To evaluate the anticarcinogenic effect and its mechanism of red ginseng, the mice were treated with red ginseng and received subcutaneous Bl6 melanoma cell line injection on the back. Tumor incidence was same (100%) both in water and red ginseng-treated groups, but tumor production was delayed in red ginseng-treated group. Survival time was somewhat longer in red ginseng-treated group. The histopathological findings were similar in both groups, but lymphocytic infiltration around the tumor and melanin production in the tumor cells were prominent in the red ginseng-treated group. Flow cytometric analysis on T lymphocytes and natural killer cells revealed increased $T_H$/$T_S$ ratio and increased NK cells in red ginseng-treated group. These results suggest that the anticarcinogenic effect of red ginseng may be exerted by the increased cell-mediated immunity and natural killer cell activity.

• Journal of Ginseng Research
• /
• v.32 no.1
• /
• pp.19-25
• /
• 2008

Lipid soluble ginseng extract was administered by oral route in doses of 600 mg/patient daily in cancer patients over 2 months and 6 months. The administration of ginseng extract in cancer patients maintained the ratio of CD4/CD8 and number of the natural killer cell in the normal range during the administration period. Also its administration showed a positive effect on tumor values in 87.5% of patients in 2 month-group and in 50% of patients in 6 month-group, as determined by various cancer markers. Liver and kidney functions maintained normal condition during administration period of 6 months. Although there was no statistical significance, these data suggest that lipid soluble ginseng extract may be useful as an adjuvant therapeutic agent and nutritional supplement for the improvement of immune function and health in cancer patients. This study would provide the basis for the research in which the antitumor and immunopotential activity of lipid soluble ginseng extract for cancer patients are evaluated in formal clinical trial with statistically significant patient number.

• The Journal of the Korean Society for Microbiology
• /
• v.22 no.3
• /
• pp.323-328
• /
• 1987

This study was attempted to investigate the effect of inosiplex on the cell-mediated immunity in the patients with lepromatous leprosy. Fourteen patients received inosiplex (6gm/day) for 1 month. About 20% of the patients (3 of 14) showed conversion of the lepromin reaction and bacteriological index was significantly decreased in 3 of 7 patients. However, inosiplex administration had no effect on the lymphocyte blastogenesis to M. leprae. The clinical evolution showed a favorable activity of the drug on cutaneous lesions in some patients. The tolerance of the drug was excellent. No side effects were observed. These results suggest that inosiplex may have a moderate immunopotential value in lepromatous leprosy.